Deals
Roche first partnered with MediLink in January 2024, likewise for an antibody-drug conjugate for solid tumors.
FEATURED STORIES
After a strong open to the year, the public markets suffered a six-month drought that led to biotech’s tightest IPO window in years.
While Novartis secured the biggest deal of the fourth quarter, a handful of riveting tales emerged from the bottom of the M&A list, including a zombie buyout and a bidding war. And no, we’re not talking about Metsera.
Four of this year’s biggest acquisitions topped 11-figure figures. One was 2025’s messiest bidding war.
Subscribe to BioPharm Executive
Market insights and trending stories for biopharma leaders, in your inbox every Wednesday
THE LATEST
Hutchison China MediTech Limited announces its unaudited financial results for the six months ended June 30, 2019 and provides updates on key clinical programs.
Funds will support UK commercial launch and FDA 510(k) submission later this year
The combined companies will have revenue drivers of two commercially available diagnostics tools, Cologuard and Oncotype DX.
The new company will be helmed by Mylan’s Michael Goettler and is expected to generate 2020 revenues of $19 to $20 billion.
Gemphire will enter into the reverse merger following a strategic review of its options.
MorphoSys AG will publish its first six months’ 2019 results on August 6, 2019 at 10:00pm CEST.
Galapagos NV announces its unaudited first half-year results, which are further detailed in its H1 2019 report available on the Galapagos website, www.glpg.com.
Eurofins Scientific, a world leader in biopharmaceutical testing acquired Alphora Research Inc. to support Eurofins’ extensive drug development platform.
Eurofins Scientific, a world leader in biopharmaceutical testing acquired Amatsigroup SAS to support Eurofins’ extensive drug development platform.
sterna biologicals selected as one of a group of top-tier European biotech companies to present at the European Biotech Investor Day on August 1, 2019 in New York City